BEM-015

BEM-015 is a humanized monoclonal antibody currently under development by Shanghai Benemae Pharmaceutical for the treatment of cardiovascular diseases. As of early 2024, the candidate is in the IND-enabling phase, progressing through CMC (Chemistry, Manufacturing, and Controls) development. While the specific molecular target has not been publicly disclosed by the developer, the drug is part of Benemae's expanding metabolic and cardiovascular pipeline, which also includes several GLP-1 receptor agonists. The progression into IND-enabling studies suggests that the molecule has demonstrated sufficient preclinical efficacy and safety to warrant advancement toward clinical trials.